A key goal of the Milner Therapeutics Consortium is to enable collaborations between Cambridge academics and our Consortium companies using forward-thinking pre-competitive models. We can now announce that the first such project has been established with Ludovic Vallier at the Wellcome MRC Cambridge Stem Cell Institute, focused on the identification of new therapeutics for liver disease. Working with GlaxoSmithKline and Ferring Pharmaceuticals, this project will bring together a novel in vitro human model for non-alcohol fatty liver disease/non-alcoholic steatohepatitis developed in the Vallier group and NASH/NAFLD expertise from the two companies. Through establishment of novel CRISPR/Cas9-based genetic screens in this model, the project aims to identify and validate new therapeutic targets.

Read more about current projects.

Ludovic Vallier